Exact Sciences Corporation maintained revenue guidance for the full year of 2024. For the period, the company has maintained its revenue guidance of $2.810 billion to $2.850 billion, assuming: screening revenue of $2.155 billion to $2.175 billion, and precision oncology revenue of $655 billion to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.85 USD | +1.93% |
|
+7.09% | -39.38% |
06-11 | Exact Sciences Seeks Acquisitions | CI |
06-11 | Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.38% | 8.28B | |
+9.28% | 3.62B | |
-1.48% | 2.24B | |
-22.85% | 1.94B | |
-18.07% | 1.72B | |
+10.53% | 962M | |
+17.17% | 734M | |
-9.17% | 690M | |
-33.88% | 477M | |
+2.58% | 298M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024